| AAV2/8-HLP-FVIII-V3 for hemophilia a | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AB-8939 for gata2 deficiency | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Abatacept for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Albipagrastim alf for febrile neutropenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ALEMTUZUMAB + Cyclophosphamide + FLUDARABINE for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ALEMTUZUMAB + Cyclophosphamide + FLUDARABINE + Melphalan for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| allogeneic hematopoietic stem cell transplantation + Pharmacological Study + CLOFARABINE + Melphalan + Sirolimus + Tacrolimus for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ANB-010, dose 1 for hemophilia a | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ANB-010, dose 2 for hemophilia a | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ANB-010, dose 3 for hemophilia a | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Antithrombin iii human for antithrombin iii deficiency | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ascorbic Acid for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn + G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn + G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Aspirin for purpura, thrombotic thrombocytopenic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ASTX727 for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ATIR101 + T-cell depleted HSCT from a related, haploidentical donor for myelodysplastic syndromes | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ATO + Ascorbic acid for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Atorvastatin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Autologous testicular tissue transplantation of prepubertal frozen testicular tissue for hematologic diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Azacitidine for anemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Azacitidine for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Azacitidine for thrombocytopenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Azacitidine + Ascorbic Acid for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Azacitidine + Ascorbic Acid for myeloproliferative disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Azacitidine + ENASIDENIB MESYLATE for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Azacitidine + Venetoclax + Mobinitinib for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AZD3632 for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AZD3632 + Posaconazole for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Benralizumab for hypereosinophilic syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Benserazide Only Product for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Benserazide Only Product for beta-thalassemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Bezuclastinib for myeloproliferative disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biospecimen Collection + Bone Marrow Aspiration + Olaparib for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BMS-986470 for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BMS-986470 + Famotidine + PANTOPRAZOLE for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BMS-986470 + Placebo for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BPA prophylaxis + Factor (FVIII or FIX) prophylaxis + FITUSIRAN for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Brentuximab vedotin for hematologic diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CID-103 for purpura | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CIPROFLOXACIN + Ceftazidime for febrile neutropenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CliniMACS + G-CSF + HPC,A Infusion + RITUXIMAB + BLINATUMOMAB + Cyclophosphamide + THIOTEPA + LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN + Mesna + FLUDARABINE + Melphalan + Sirolimus + Tacrolimus for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CliniMacs TCR alpha-beta-Biotin system for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Clotting factor concentrates (CFC) or bypassing agents (BPA) + EMICIZUMAB + FITUSIRAN + ANTITHROMBIN III HUMAN for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Clotting factor concentrates (CFC) or bypassing agents (BPA) + FITUSIRAN + ANTITHROMBIN III HUMAN for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) for anemia, sickle cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Crizanlizumab for anemia, sickle cell | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CSL222 (AAV5-hFIXco-Padua) for hemophilia b | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua) for hemophilia b | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cyclophosphamide for anemia, refractory, with excess of blasts | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cyclophosphamide for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CYTARABINE + Cladribine + Azacitidine + Venetoclax for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Danicopan for hemoglobinuria, paroxysmal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Darbepoetin alfa + canakinumab for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Decitabine + ARSENIC TRIOXIDE for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Decitabine + QUIZARTINIB + Venetoclax for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| DIAG723 for telangiectasia, hereditary hemorrhagic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Donor Leukocyte Infusion (DLI) + INTERFERON GAMMA-1B for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Donor mobilized PBSC infusion + G-CSF + RITUXIMAB + Cyclophosphamide + MP + FLUDARABINE for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Donor mobilized PBSC infusion + G-CSF + Total Body Irradiation (TBI) (Plan 1) + RITUXIMAB + Cyclophosphamide + MP + FLUDARABINE for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for anemia, sickle cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| EDIT-301 for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| efanesoctocog alfa (BIVV001) for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Elritercept for anemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Elritercept for myelodysplastic syndromes | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Exagamglogene autotemcel for anemia, sickle cell | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
|---|
| Exagamglogene autotemcel for beta-thalassemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Exerenibart for beta-thalassemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Fidanacogene Elaparvovec for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Fidanacogene Elaparvovec for hemophilia b | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
|---|
| Fitusiran for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
|---|
| Fitusiran for hemophilia b | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + Mitoxantrone + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Mitoxantrone + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + Stem Cell Transplant + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| G-CSF + ITMHA + Stem Cell Transplant + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Givinostat for primary myelofibrosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Givinostat for thrombocythemia, essential | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Busulfan + FLUDARABINE + Melphalan + Mycophenolate Mofetil Hydrochloride for anemia, refractory, with excess of blasts | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Total Body Irradiation (TBI) + Cyclophosphamide + FLUDARABINE + Mycophenolate Mofetil Hydrochloride + Tacrolimus for anemia, refractory, with excess of blasts | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GVHD prophylaxis regimen + RIC regimen for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GVHD prophylaxis regimen + RIC regimen for bone marrow failure disorders | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Hematopoietic stem-cell transplantation for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| HMB-002 (Part A) for von willebrand disease, type 3 | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| HMB-002 (Part B) for von willebrand disease, type 3 | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US) for von willebrand disease, type 3 | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Hydroxycarbamide for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Iloprost for vaso-occlusive crises | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Imatinib Mesylate for hypereosinophilic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Immediate HSCT Group for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Iron sucrose for anemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Isatuximab for anemia, aplastic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for myelodysplastic syndromes | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for myeloproliferative disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for myelodysplastic syndromes | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for myeloproliferative disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Luspatercept for anemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
|---|
| Luspatercept for myelodysplastic syndromes | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Luspatercept for primary myelofibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Lusutrombopag combined with recombinant human thrombopoietin for thrombocytopenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Marstacimab for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Marstacimab for hemophilia b | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Mitapivat for anemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Mobilized CD34-selected Peripheral Blood Stem Cell graft for anemia, refractory, with excess of blasts | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Mobinitinib for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Momelotinib for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Navitoclax for primary myelofibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nintedanib for telangiectasia, hereditary hemorrhagic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nk-dli for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peginterferon α-2b injection for thrombocythemia, essential | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pelabresib for primary myelofibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for primary myelofibrosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peripheral Blood Stem Cell Transplantation + Hematopoietic Cell Transplantation + Laboratory Biomarker Analysis + Quality-of-Life Assessment + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for anemia, refractory, with excess of blasts | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for congenital bone marrow failure syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for hemoglobinopathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 2 Established Dose from prior study, NCT03810196 for anemia, refractory, with excess of blasts | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 2 Established Dose from prior study, NCT03810196 for congenital bone marrow failure syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 2 Established Dose from prior study, NCT03810196 for hemoglobinopathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 2 Maximum Tolerated Dose determined in Phase 1 for anemia, refractory, with excess of blasts | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 2 Maximum Tolerated Dose determined in Phase 1 for congenital bone marrow failure syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 2 Maximum Tolerated Dose determined in Phase 1 for hemoglobinopathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Placebo for Oral Azacitidine for anemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Placebo for Oral Azacitidine for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Placebo for Oral Azacitidine for thrombocytopenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pozelimab + cemdisiran for hemoglobinuria, paroxysmal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton Total Marrow Irradiation for anemia, refractory, with excess of blasts | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia for anemia, aplastic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| RITUXIMAB + Cyclophosphamide + MP + Busulfan + FLUDARABINE for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rivogenlecleucel + rimiducid for anemia, aplastic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rivogenlecleucel + rimiducid for cytopenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rivogenlecleucel + rimiducid for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Romiplostim for anemia, aplastic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Romiplostim for anemia, refractory, with excess of blasts | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ROPEGINTERFERON ALFA-2B for thrombocythemia, essential | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rosuvastatin for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ruxolitinib for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ruxolitinib + NAVITOCLAX for primary myelofibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ruxoprubart for hemoglobinuria, paroxysmal | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Selinexor for primary myelofibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonrotoclax for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonrotoclax for myelodysplastic-myeloproliferative diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonrotoclax + Azacitidine for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonrotoclax + Azacitidine for myelodysplastic-myeloproliferative diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonrotoclax + Posaconazole + Azacitidine for myelodysplastic syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonrotoclax + Posaconazole + Azacitidine for myelodysplastic-myeloproliferative diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SPK-8011QQ for hemophilia a | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SR604 for factor vii deficiency | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| SR604 for hemophilia a | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SR604 for hemophilia b | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SR604 for von willebrand diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Stem Cell Infusion + Total Body Irradiation + Cyclophosphamide + Mycophenolate Mofetil + TREOSULFAN + FLUDARABINE + Tacrolimus for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tasquinimod for primary myelofibrosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TASQUINIMOD + Ruxolitinib for primary myelofibrosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation for anemia, sickle cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| thrombopoietin receptor agonist (TPO-RA) + Cyclosporine + ROMIPLOSTIM for anemia, aplastic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blasts | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + THIOTEPA + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blasts | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tranexamic acid for anemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tretinoin for thrombocytopenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ULIXERTINIB + Ruxolitinib for primary myelofibrosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Unmanipulated Bone Marrow Graft with Cyclophosphamide + Cyclophosphamide for anemia, refractory, with excess of blasts | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Venetoclax + AB-8939 for gata2 deficiency | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Venetoclax + FLUDARABINE for myelodysplastic syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vitamin C (ascorbic acid) for cytopenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vitamin C (ascorbic acid) for myelodysplastic syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Zemocimig for hemophilia a | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|